| PKD Program - Enrolment Target Met | Nov 12, 2026 | Other filings | ASX |
|---|
| Results of Annual General Meeting | Nov 11, 2026 | Meeting outcome | ASX |
|---|
| 2026 Annual General Meeting Program and CEO Presentation | Nov 11, 2026 | Meeting notice | ASX |
|---|
| Notification regarding unquoted securities - PYC | Nov 9, 2026 | Other filings | ASX |
|---|
| Change of Director's Interest Notice | Nov 5, 2026 | Ownership change notice | ASX |
|---|
| Annual General Meeting - Conference Link | Nov 4, 2026 | Meeting notice | ASX |
|---|
| Change of Director's Interest Notice | Nov 3, 2026 | Ownership change notice | ASX |
|---|
| Change of Director's Interest Notice | Oct 30, 2026 | Ownership change notice | ASX |
|---|
| Exercise of Options and Cleansing Notice | Oct 29, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - PYC | Oct 29, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 28, 2026 | Quarterly report | ASX |
|---|
| PKD Program - ASN Presentation | Oct 22, 2026 | Operations update | ASX |
|---|
| Exercise of Options and Cleansing Notice | Oct 15, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 11, 2026 | Meeting notice | ASX |
|---|
| Application for quotation of securities - PYC | Oct 7, 2026 | Financing | ASX |
|---|
| Notification of cessation of securities - PYC | Oct 7, 2026 | Financing | ASX |
|---|
| PKD Program - Presentation of Data at ASN Conference | Oct 6, 2026 | Operations update | ASX |
|---|
| RP11 PROGRAM - PRESENTATION AT EURETINA 2026 | Oct 1, 2026 | Other filings | ASX |
|---|
| PKD - First Patient Dosed in OLE Study | Sep 10, 2026 | Operations update | ASX |
|---|
| S&P DJI Announces September 2026 Quarterly Rebalance | Sep 4, 2026 | Other filings | ASX |
|---|
| Investor Webinar Presentation Q3 2026 | Sep 3, 2026 | Other filings | ASX |
|---|
| ADOA Program - Data Presentation | Sep 2, 2026 | Other filings | ASX |
|---|
| Ceasing to be a substantial holder | Sep 2, 2026 | Ownership change notice | ASX |
|---|
| PKD - Presentation of Clinical Safety Data | Aug 30, 2026 | Other filings | ASX |
|---|
| 2026 Corporate Governance Statement | Aug 28, 2026 | Other filings | ASX |
|---|
| Appendix 4G | Aug 28, 2026 | Other filings | ASX |
|---|
| 2026 Annual Report to Shareholders | Aug 28, 2026 | Annual report | ASX |
|---|
| Appendix 4E | Aug 28, 2026 | Results | ASX |
|---|
| Notification regarding unquoted securities - PYC | Aug 26, 2026 | Other filings | ASX |
|---|
| Investor Webinar | Aug 17, 2026 | Other filings | ASX |
|---|
| Change of Director's Interest Notice | Aug 13, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - PYC | Aug 13, 2026 | Other filings | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 28, 2026 | Quarterly report | ASX |
|---|
| PKD - Safety Committee Approves Dose Escalation | Jul 21, 2026 | Other filings | ASX |
|---|
| ADOA Program Update | Jul 20, 2026 | Other filings | ASX |
|---|
| PKD - Initiation of Multiple Dose Clinical Trial | May 6, 2026 | Other filings | ASX |
|---|
| Presentation of Ophthalmology Clinical Trial Data at ARVO | May 3, 2026 | Operations update | ASX |
|---|
| ADOA Program - SRC Approve Progression to Multi-Dose Study | Apr 15, 2026 | Other filings | ASX |
|---|
| Completion of Retail Entitlement Offer | Mar 3, 2026 | Financing | ASX |
|---|
| PKD Clinical Trial - Approval to Escalate Dosing | Feb 26, 2026 | Operations update | ASX |
|---|
| Half Yearly Report and Accounts | Feb 23, 2026 | Interim report | ASX |
|---|
| Retail Offer Booklet | Feb 8, 2026 | Offer document | ASX |
|---|
| Completion of Placement and Institutional Entitlement Offer | Feb 3, 2026 | Financing | ASX |
|---|
| PYC Raising up to $653m to Deliver Human Efficacy Data | Feb 1, 2026 | Financing | ASX |
|---|
| PYC Capital Raising Presentation | Feb 1, 2026 | Offer document | ASX |
|---|
| Trading Halt | Feb 1, 2026 | Trading halt or suspension | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 22, 2026 | Quarterly report | ASX |
|---|
| PKD Clinical Trial - Safety Outcomes in Part A | Dec 18, 2025 | Operations update | ASX |
|---|
| Sustained Vision Improvement in RP11 Patients | Nov 13, 2025 | Operations update | ASX |
|---|
| ADOA Program Initiation of Global Repeat Dose Study | Oct 20, 2025 | Other filings | ASX |
|---|
| PMS Program Data Supports Progression to Human Trials | Oct 12, 2025 | Other filings | ASX |
|---|
| ADOA Program Progressing to Multiple Dose Study | Oct 8, 2025 | Other filings | ASX |
|---|
| Board and Management Changes | Sep 21, 2025 | Management or board change | ASX |
|---|
| Correction to Trading Halt Request | Sep 19, 2025 | Trading halt or suspension | ASX |
|---|
| Change of Managing Director | Sep 16, 2025 | Management or board change | ASX |
|---|
| ADOA Program - Presentation of Clinical Data at NOSA 2025 | Sep 4, 2025 | Other filings | ASX |
|---|
| PKD Program - Presentation of Safety Data at ANZSN | Aug 28, 2025 | Other filings | ASX |
|---|
| Appendix 4E | Aug 28, 2025 | Results | ASX |
|---|
| Approval to Escalate Dosing in Kidney Disease Clinical Trial | Aug 7, 2025 | Operations update | ASX |
|---|
| Approval to Progress Kidney Disease Trial to Next Stage | Jul 6, 2025 | Operations update | ASX |
|---|
| Fourth Drug Program Progressing to Human Trials | Jun 26, 2025 | Other filings | ASX |
|---|
| FDA Alignment on Registrational Trial Design RP11 Program | Jun 22, 2025 | Other filings | ASX |
|---|
| SRC Approves Dose Escalation in ADOA Clinical Trial | Jun 10, 2025 | Other filings | ASX |
|---|
| Approval to Escalate Dosing in Kidney Disease Trial | May 25, 2025 | Operations update | ASX |
|---|
| Presentation of Clinical Proof of Concept in Lead Program | Apr 27, 2025 | Other filings | ASX |
|---|
| Completion of Entitlement Offer | Apr 16, 2025 | Financing | ASX |
|---|
| First Subject Dosed in PKD Clinical Trial | Apr 9, 2025 | Other filings | ASX |
|---|
| Placement of Shortfall | Apr 9, 2025 | Financing | ASX |
|---|
| Retail Entitlement Offer Booklet | Feb 24, 2025 | Offer document | ASX |
|---|
| Completion of Institutional Entitlement Offer | Feb 18, 2025 | Financing | ASX |
|---|
| PYC Equity Raising Presentation | Feb 16, 2025 | Offer document | ASX |
|---|
| PYC Equity Raising to Raise up to $146 Million | Feb 16, 2025 | Financing | ASX |
|---|
| Approval to Commence Human Trials in Kidney Program | Feb 9, 2025 | Other filings | ASX |
|---|
| ADOA Safety Review Committee Approves Dose Escalation | Jan 30, 2025 | Operations update | ASX |
|---|
| US FDA Grants Rare Pediatric Disease Designation to VP-001 | Jan 19, 2025 | Other filings | ASX |
|---|
| PYC Nominates Fourth Clinical Drug Candidate in PMS Program | Dec 15, 2024 | Other filings | ASX |
|---|
| PYC to Progress Kidney Drug Candidate Into Human Trials | Nov 26, 2024 | Other filings | ASX |
|---|
| Consolidation/Split - PYC | Nov 11, 2024 | Other filings | ASX |
|---|
| RP11 SRC Approves Dose Escalation to Final Patient Cohort | Nov 4, 2024 | Other filings | ASX |
|---|
| First ADOA Patient Dosed in Clinical Trial | Oct 31, 2024 | Other filings | ASX |
|---|
| Interim Update on Progress in RP11 Repeat Dose Trials | Oct 21, 2024 | Interim report | ASX |
|---|
| US FDA Grants Orphan Drug Designation to PYC Drug Candidate | Oct 20, 2024 | Other filings | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 14, 2024 | Meeting notice | ASX |
|---|
| FDA Grants Rare Pediatric Disease Designation to PYC-001 | Aug 29, 2024 | Other filings | ASX |
|---|
| Appendix 4E and Audited Financial Statements | Aug 29, 2024 | Results | ASX |
|---|
| PYC to Start Human Trials in Second Blinding Eye Disease | Aug 14, 2024 | Other filings | ASX |
|---|
| Visual Improvement in Multiple RP11 Patients | Aug 11, 2024 | Other filings | ASX |
|---|
| RP11 Clinical Trial Update - Amended | Aug 5, 2024 | Other filings | ASX |
|---|
| RP11 Clinical Trial Update | Aug 4, 2024 | Operations update | ASX |
|---|
| Extension of RP11 Single Dose Study Into Multiple Dose Study | Jul 22, 2024 | Operations update | ASX |
|---|
| Initial Dosing Completed in Cohort 1 of RP11 MAD Study | Jul 16, 2024 | Operations update | ASX |
|---|
| Commencement of RP11 Multiple Dose Trial | Jul 9, 2024 | Operations update | ASX |
|---|
| RP11 Drug Candidate Safe and Well Tolerated | Jun 30, 2024 | Other filings | ASX |
|---|
| PMS Drug Candidate Effective In Human Brain Cells | Jun 6, 2024 | Operations update | ASX |
|---|
| RP11 Clinical Trial Dosing Completed in Cohort 4 | May 15, 2024 | Operations update | ASX |
|---|
| Successful GLP Tox Studies in Second Blinding Eye Disease | May 13, 2024 | Operations update | ASX |
|---|
| Presentation of RP11 Clinical Trial Data at ARVO Conference | May 5, 2024 | Other filings | ASX |
|---|
| RP11 Drug Candidate Progressing to Mid-Stage Human Trials | Apr 28, 2024 | Other filings | ASX |
|---|
| Kidney Disease Drug Candidate Progressing to Human Trials | Apr 21, 2024 | Operations update | ASX |
|---|
| $74.6 Million Extension of Cash Runway | Apr 10, 2024 | Financing | ASX |
|---|
| PYC Equity Raising to Raise up to $74.6 Million | Mar 13, 2024 | Financing | ASX |
|---|
| RP11 Clinical Trial - Dosing Completed in Cohort 3 | Feb 27, 2024 | Operations update | ASX |
|---|
| Receipt of $4.5m Collaboration Fee | Feb 16, 2024 | Other filings | ASX |
|---|
| AI Driven Drug Discovery Collaboration with Google Cloud | Jan 1, 2024 | Operations update | ASX |
|---|
| RP11 Clinical Trial Progressing To High Dose Cohort | Dec 17, 2023 | Other filings | ASX |
|---|
| Response to Price Query | Nov 30, 2023 | Explanation request | ASX |
|---|
| Supplementary Information | Nov 16, 2023 | Other filings | ASX |
|---|
| New Drug For Major Kidney Disease Effective In Human Models | Nov 12, 2023 | Other filings | ASX |
|---|
| PYC and FDA Align On Clinical Trial Pathway in ADOA | Nov 5, 2023 | Operations update | ASX |
|---|
| RP11 Clinical Trial Dosing Completed In Patient Cohort 2 | Nov 2, 2023 | Operations update | ASX |
|---|
| PYC-001 Effective In Both NHPs and Patient-Derived Models | Oct 3, 2023 | Other filings | ASX |
|---|
| Safety Review Committee Approves Dose Escalation | Sep 21, 2023 | Other filings | ASX |
|---|
| RP11 Clinical Trial Dosing Completed In Patient Cohort 1 | Aug 17, 2023 | Other filings | ASX |
|---|
| PYC Increases Ownership of VP-001 Program | Aug 9, 2023 | Other filings | ASX |
|---|
| PYC Receives FDA Fast Track Designation | Aug 1, 2023 | Other filings | ASX |
|---|
| Successful Toxicology Results Pave Way for Phase 2 Trial | Jul 17, 2023 | Other filings | ASX |
|---|
| FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL | Jun 29, 2023 | Other filings | ASX |
|---|
| Placement Supporting Document | May 11, 2023 | Financing | ASX |
|---|
| Successful Completion of $30m Placement | May 10, 2023 | Financing | ASX |
|---|
| Commencement of First Clinical Study in RP11 | Apr 25, 2023 | Other filings | ASX |
|---|
| Second Drug Program Progressing to Human Trials | Apr 3, 2023 | Other filings | ASX |
|---|
| FDA Clears PYC to Commence First Human Trials in RP11 | Mar 5, 2023 | Other filings | ASX |
|---|
| VP-001 IND Lodgement | Feb 1, 2023 | Other filings | ASX |
|---|
| Successful Toxicology Studies Pave Way for Human Trials | Nov 6, 2022 | Other filings | ASX |
|---|
| Central Nervous System Drug Program Added to PYC Pipeline | Sep 26, 2022 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 30, 2022 | Results | ASX |
|---|
| PYC Increases Shareholding in Vision Pharma | Feb 16, 2022 | Other filings | ASX |
|---|
| Quarterly Activities and Appendix 4C Cash Flow Report | Jan 26, 2022 | Quarterly report | ASX |
|---|
| Successful Completion of Key Translational Milestone | Nov 15, 2021 | Other filings | ASX |
|---|
| Retina Target Engagement Confirmed in Large Eye | Sep 29, 2021 | Other filings | ASX |
|---|
| Second Drug Program Progressing Towards Human Trials | Jun 8, 2021 | Other filings | ASX |
|---|
| March 2021 Quarterly Report and Cashflow | Apr 29, 2021 | Quarterly report | ASX |
|---|
| Lead Investigational Drug Demonstrates Key Improvement | Mar 1, 2021 | Legal or regulatory action | ASX |
|---|
| Half Year Accounts and Appendix 4D | Feb 26, 2021 | Interim report | ASX |
|---|
| Progress US Clinical Stage Company and Corporate Objectives | Feb 21, 2021 | Other filings | ASX |
|---|
| Quarterly Activities Report and Appendix 4C | Jan 29, 2021 | Quarterly report | ASX |
|---|
| Visual Evidence of Lead Drugs Efficacy | Dec 15, 2020 | Other filings | ASX |
|---|
| Review of Activities and Appendix 4C | Oct 26, 2020 | Quarterly report | ASX |
|---|
| Successful Institutional Entitlement Offer and Placement | Oct 21, 2020 | Financing | ASX |
|---|
| PYC Business and Equity Raising Presentation | Oct 19, 2020 | Other filings | ASX |
|---|
| PYC Equity Raising to Raise up to $55 Million | Oct 19, 2020 | Other filings | ASX |
|---|
| New Drug for Substantial Unmet Need Added to Pipeline | Oct 11, 2020 | Other filings | ASX |
|---|
| PYCs Lead Drug Effective in Patient Derived Models Tested | Oct 6, 2020 | Other filings | ASX |
|---|
| Second Potential Blockbuster Drug Added to PYCs Pipeline | Oct 4, 2020 | Other filings | ASX |
|---|
| Creation of Novel Gene Therapy Delivery Technology | Sep 7, 2020 | Other filings | ASX |
|---|
| Appendix 4E Preliminary Final Report | Aug 31, 2020 | Results | ASX |
|---|
| Executive re-structure across global operations | Aug 19, 2020 | Other filings | ASX |
|---|
| Shareholder Update - Forward View 2020 Milestones | Aug 4, 2020 | Other filings | ASX |
|---|
| June 2020 Quarterly Activity Report and Cashflow | Jul 30, 2020 | Other filings | ASX |
|---|
| Successful Dose Response & Toxicity Studies in Lead Program | Jul 21, 2020 | Other filings | ASX |
|---|
| S&P DJI Announces June 2020 Quarterly Rebalance | Jun 11, 2020 | Other filings | ASX |
|---|
| March 2020 Quarterly Activities and Cash Flow Report | Apr 29, 2020 | Quarterly report | ASX |
|---|
| Successful Efficacy Result on Path to First in Human Studies | Mar 31, 2020 | Other filings | ASX |
|---|
| Investor Presentation - February 2020 | Feb 23, 2020 | Other filings | ASX |
|---|
| CEO Appointment and Establishment of US Office | Feb 12, 2020 | Other filings | ASX |
|---|
| Expansion Of Drug Development Pipeline | Feb 2, 2020 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Jan 31, 2020 | Quarterly report | ASX |
|---|
| Quarterly Shareholder Update | Jan 5, 2020 | Other filings | ASX |
|---|
| Drug Delivery Greater Than 100% More Effective In Animals | Dec 1, 2019 | Other filings | ASX |
|---|
| Conclusion of Genentech Antimicrobial Collaboration | Nov 14, 2019 | Other filings | ASX |
|---|
| Retail Offer Document | Nov 3, 2019 | Offer document | ASX |
|---|
| PYCs Institutional Entitlement Offer Closes | Nov 3, 2019 | Financing | ASX |
|---|
| Entitlement Offer - Investor Presentation | Oct 31, 2019 | Financing | ASX |
|---|
| $26.8m Fully Underwritten Accelerated Entitlement Offer | Oct 30, 2019 | Financing | ASX |
|---|
| Sept 2019 Quarterly Shareholder Update and Appendix 4C | Oct 30, 2019 | Quarterly report | ASX |
|---|
| Successful Major Milestone - Human Retina in a Dish Models | Oct 8, 2019 | Other filings | ASX |
|---|
| Strategic Partnership and Lead Program | Oct 1, 2019 | Other filings | ASX |
|---|
| Successful Time-Course Studies in Animals | Sep 25, 2019 | Other filings | ASX |
|---|
| Successful Competitive Drug Evaluation in Animals | Sep 2, 2019 | Other filings | ASX |
|---|
| Successful Time - Course Studies in Animals | Aug 22, 2019 | Other filings | ASX |
|---|
| Response to ASX Aware Query | Aug 7, 2019 | Explanation request | ASX |
|---|
| Phylogicas Technology is Effective in Human Cells | Aug 6, 2019 | Other filings | ASX |
|---|
| Company Presentation - July 2019 | Jul 23, 2019 | Other filings | ASX |
|---|
| Operational Update and Appendix 4C | Jul 23, 2019 | Quarterly report | ASX |
|---|
| Animal Models - 400% Outperformance of Gold Standard | Jul 22, 2019 | Other filings | ASX |
|---|
| Break Through Animal Model Results | Jun 26, 2019 | Other filings | ASX |
|---|
| March 2019 Quarterly Operational Update and App4C | Apr 29, 2019 | Other filings | ASX |
|---|
| Collaboration Agreement - siRNA delivery | Mar 13, 2019 | Other filings | ASX |
|---|
| Flagship Program - Successful Animal Models | Mar 11, 2019 | Other filings | ASX |
|---|
| First Competitive Read Out - Peptide Vaccine | Feb 8, 2019 | Other filings | ASX |
|---|
| Dec 2018 Operational Update and App4C | Jan 31, 2019 | Other filings | ASX |
|---|
| CEO letter and Operational Update | Jan 16, 2019 | Other filings | ASX |
|---|
| In Vivo Success - peptide vaccine (Amended Graphics) | Dec 6, 2018 | Other filings | ASX |
|---|
| In vivo success - peptide vaccine in Herpes Simplex Virus | Dec 6, 2018 | Other filings | ASX |
|---|
| Successful Delivery of CRIPR/Cas9 into Cells ex vivo | Dec 3, 2018 | Other filings | ASX |
|---|
| FNA Presentation | Nov 22, 2018 | Other filings | ASX |
|---|
| AGM Company Presentation | Nov 16, 2018 | Other filings | ASX |
|---|
| Sept 2018 Quarterly Operations Update and App4C | Oct 31, 2018 | Operations update | ASX |
|---|
| Fourfold Delivery Improvement in a New Lead Candidate | Oct 29, 2018 | Other filings | ASX |
|---|
| R&D Tax Incentive Refund | Oct 8, 2018 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation | Sep 11, 2018 | Trading halt or suspension | ASX |
|---|
| Phylogica Recapitalisation | Sep 11, 2018 | Other filings | ASX |
|---|
| Suspension from Official Quotation | Sep 10, 2018 | Trading halt or suspension | ASX |
|---|
| Update on Capital Raising | Sep 10, 2018 | Financing | ASX |
|---|
| June 2018 Quarterly Operational Update and App4C | Jul 31, 2018 | Other filings | ASX |
|---|
| Achievement of Major Milestone - In vivo Cre Delivery | Jul 30, 2018 | Other filings | ASX |
|---|
| Successful In-vivo Results Peptide Vaccine T-Cell Expansion | Jul 26, 2018 | Other filings | ASX |
|---|
| CEO Update | Jul 8, 2018 | Other filings | ASX |
|---|
| March 2018 Operational Update and Cashflow | Apr 30, 2018 | Other filings | ASX |
|---|